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Experimental allergic encephalomyelitis (EAE) is widely regarded as a labora-
tory analog of multiple sclerosis (MS) . Recent evidence both in MS and EAE
point to the fact that activated macrophages appear to be proximal agents of
myelin destruction (1) . In view of these findings and encouraged by the prelim-
inary results of a trial of colchicine in MS patients, we asked the question whether
or not colchicine might be effective in the prevention of EAE .
Colchicine is a unique antiinflammatory agent whose traditional use has been
in the treatment and prophylaxis of acute gout (2) . In addition, colchicine is also
effective against a variety of inflammatory disorders such as familial Mediterra-
nean fever and Behcet's disease which resemble MS in their cardinal features of
recurrent inflammation and enhanced chemotaxis and phagocytosis .
Murine EAE was induced both by active sensitization of animals with neural
antigens and by adoptive transfer of encephalitogenic T cells . The results
obtained clearly show that colchicine blocks the appearance of EAE and appears
to exert its inhibitory effects mainly on the efferent limb of theimmune response .
Materials and Methods
Animals.
￿
Female SJL/J or (SJL/J x BALB/c)F, hybrid mice, 6-10 wk of age were
obtained from The Jackson Laboratory, Bar Harbor, ME.
Induction ofAcute EAE .
￿
The method of Linthicum and Frelinger (3) was used for the
active induction of EAE . Mice were examined daily for signs of EAE and scored on a
scale of 0-3, as described in this paper .
Adoptive Transfer ofEAE .
￿
The method of Pettinelli and McFarlin (4) was followed,
using SJL/J female mice .
Colchicine Treatment.
￿
Intravenous colchicine (Eli Lilly and Co ., Indianapolis, IN), was
injected in test mice intraperitoneally on alternate days or as otherwise indicated in the
text at a dosage level of 15 Ag in 0.1 ml . Peripheral blood counts of mice showed no
change after 14 d of colchicine treatment . Control mice were injected intraperitoneally
with water .
MeasurementofDelayed-Type Hypersensitivity (DTH).
￿
The footpad swelling test was used
to measure the effect of colchicine on DTH responses to bovine myelin basic protein
(MBP) and the unrelated antigen PPD . Mice were injected subcutaneously at three sites
in the flanks with the appropriate antigen in a total of 0.1 ml CFA with added Mycobacte-
rium tuberculosis (H37RA ; Difco Laboratories Inc ., Detroit, MI) . For challenge, antigen
in saline or saline alone was injected into interdigital pads in a volume of 10 pl using a
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Effect of Colchicine on the Development ofAcute EAE
TABLE I
* 6,ug dry of mouse spinal cord in 0.1 ml CFAwith 500,ug M. tuberculosis (H37RA; Difco) added was injected into
the four footpads. Immediately thereafter and 48 hlater B. pertussis, 25 x 109cell in 0.2 ml, was injected via the
tail vein. The B. pertussis was kindly provided by Dr. D. S. Linthicum, University of Southern California, Los
Angeles.
$ Twoanimals had ruffled fur with weight loss and tail atonia for <2 d.
9 In order ofincreasing severity, ± through ++++.
I0Al syringe (Hamilton Co., Reno, NV) fitted with a 30-gauge needle. Footpad swelling
was measured before and after challenge using a spring-loaded dial gauge caliper (Peacock
Laboratories, Inc., Philadelphia, PA).
Immunocytochemistry : Staining for Ia Antigen.
￿
The avidin-biotin complex (ABC) tech-
nique as described by Traugott et al. was used on frozen sections of brain and spinal cord
from colchicine-treated and control EAE hybrid mice. la-bearing cells were localized by
use of mouse mAb against the H-2d phenotype (Becton Dickinson & Co., Mountain View,
CA).
Histopathology.
￿
Glutaraldehyde perfused tissues were embedded in EPON and 1-,um
sections were stained with toluidine blue for light microscopy. Perfusion with 20%
formalin in PBS was used for the preparation of paraffin-embedded sections to be stained
with H and E, luxol fast blue and Bodian stain.
Results
Effect of Colchicine on Development of Acute EAE.
￿
EAE was induced in female
SJL/J x BALB/c mice after immunization with spinal cord antigens in the
presence of CFA and Bordetella pertussis. 25 of 30 immunized animals developed
classical clinical signs of EAE between 12 and 18 d after immunization. Colchicine
treatment begun on day -1 resulted in complete prevention of clinical EAE in
an experimental group of 30 mice. When colchicine treatment was begun on day
7 after immunization, EAE was found to develop in 11 of 15 mice indicating
that colchicine must be given early after sensitization to prevent disease. The
results of these experiments are summarized in Table 1 .
Five animals from each group were killed for histology. All five EAE animals
from the untreated group showed inflammatory cell infiltrates in the brain and
spinal cord consisting of mononuclear cells and small numbers of polymorpho-
nuclear leukocytes. Luxol fast blue and Bodian stains showed areas of demyeli-
nation with relative axonal sparing. Toluidine blue-stained Epon sections and
electron microscopy (not shown) confirmed the presence of focal demyelination
associated with inflammatory mononuclear cells.
Five colchicine-protected animals showed a mild mononuclear cell infiltrate in
the leptomeninges at the base of the brain, and no demyelination was seen in the
brain and spinal cord of these animals. EAE animals from the group with delayed
colchicine treatment had pathological lesions similar to the untreated EAE
animals, but of definite reduced severity.
Croup
Number of
animals
immunized*
Colchicine treatment
(15 mg)
Number
with clinical
EAEper
total number
at risk
Disability
score
Histopa-
thology
grade§
la
expres-
sion
I 30 None 25/30 2-3 ++++ +
II 30 Intraperitoneally from day -1 2/30* 0 ± -
after infection and every
other day
111 15 Intraperitoneally from day +7 11/15 2 + ND
and every other dayLYONS ET AL.
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TABLE 11
Effect of Colchicine on Adoptive Transfer ofEAE by Lymph Node Cells (LNC) Culturedfor
96 h with MBP
* Five SJL/J mice for each group were sensitized by subcutaneous injection into the flanks of 400 tug bovine MBP
in 0.1 ml ofa CFA emulsion with 50 Wg M. tuberculosis (H37RA) added.
Immunostaining for endothelial cell la expression was performed on spinal
cord tissue from three EAE animals and three colchicine-protected animals. The
spinal cords ofthe mice with acute EAE exhibited significant la staining ofblood
vessel endothelium, while colchicine-treated animals were essentially negative.
Effect of Colchicine on Adoptive Transfer of EAE.
￿
Two groups of female SJL/J
mice were immunized as described (4). One group was treated with colchicine
beginning on the day before immunization and continued every other day until
LNC harvest on day 12 after immunization. LNC were cultured with MBP for
96 hours, washed and counted and injected into four groups of recipient SJL/J
mice according to the protocol outlined in Table 11.
LNC from donor animals treated with colchicine from the day before immu-
nization failed to transfer EAE (group I1), while LNC from control animals
produced EAE in all recipients between days 9-11 after transfer (group IA).
Pretreatment of recipients with colchicine (on days -3 and -1 before cell
transfer) had no effect on subsequent development ofEAE (group III). However,
colchicine treatment of recipients concurrent with cell transfer resulted in
complete prevention of EAE development (group IC). Histopathological evalu-
ation of spinal cord from these animals showed the presence of sparse mononu-
clearinfiltratesaround blood vessels in 3 of 15 sections examined andno evidence
ofdemyelination. In contrast, animals with EAE showed dense inflammatory cell
infiltrations with associated areas ofdemyelination in 15 of 15 sections of spinal
cord examined (see Fig. 1).
Effect of Colchicine on DTH Responses.
￿
Three groups of SJL/J mice were
sensitized with MBP in CFA and added M. tuberculosis and were challenged 4 d
later by intrafootpad injection of MBP in saline. One group was treated with
colchicine on days 1 and 3 after sensitization, and a second group was treated on
day 4. The third group served as a non-colchicine-treated control. The results
are presented in Fig. 2. Colchicine treatment on days 1 and 3 after sensitization
had a potentiating effect on DTH. Colchicine on day 4, however, suppressed
DTH expression. Identical results were obtained when an unrelated antigen
PPD was used in place ofMBP for sensitization and challenge (results not shown).
Group Treatment ofdonor mice* Treatment of recipient mice
Outcome:
incidence
of EAE
IA Sensitized with MBP in CFA plus 4 X 10' stimulated LNG injected intrave- 5/5
M. tuberculosis nously.
IB As in IA 4 X 10' stimulated LNC injected intrave- 5/5
nously; animals pretreated with colchicine
day -3 and -1
IC As in IA 4 X 10' stimulated LNC injected intrave- 0/5
nously; animals treated with colchicine
from day of injection (day 0) and every
other day
11 Sensitized as in group 1; treated 4 X 10' stimulated LNC injected intrave- 0/5
with colchicine from day -1 nously
and every other day until LNC
harvest on day 121806
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FIGURE 1 .
￿
Photomicrographs of toluidine blue-stained 1-Am EPON sections from lumbar
spinal cords ofmice with EAE (A) andwithout EAE after colchicine treatment during adoptive
transfer (B) . (A) Several demyelinated axons are seen in the central area (arrows) in proximity
to numerous mononuclear inflammatory cells (curved arrows). Intact axons ofthe anterior root
(peripheral nerve) are seen in upper right corner . (B) Mild perivascular infiltration is seen
(arrow) . Spinal cord axons appear normal (below vessel and lower left). Normal appearing
posterior root axons are on upper right. X 200LYONS ET AL.
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FIGURE 2.
￿
Effect of colchicine on DTH reaction to MBP in SJL/J mice. Three groups of
five mice were sensitized as describedin Materials andMethods using 200 Ag bovine MBP per
mouse (day 0). Intrafootpad challenge used 50 jug of MBP in saline (day 4). Footpad swelling
was measured on days 5, 6, and 7 and group means were calculated. Footpad swelling index
(FSI) was calculated from the following: FSI = {[(L-Lo)/Lo]-[(R-Ro)/Rol X 1001 whereL and
Lo representleft footpad thicknessafter (L) andbefore (Lo) challenge with antigen, and R and
Ro represent right foodpad thicknessafter (R) and before (Ro) saline control inoculation.
Discussion
The present studies show that colchicine effectively prevents the development
of the clinical signs and histological lesions of acute, monophasic EAE in mice.
However, ifadministration wasdelayed until day 7afterimmunization, treatment
was relatively ineffective (Table 1).
As noted by Traugott etal. (5), la molecules can be shown on endothelial cells,
as well as on small numbers of mononuclear inflammatory cells within the CNS,
within 7 d after immunization, suggesting an important role for these molecules
in the induction of EAE. This may explain the relative ineffectiveness of colchi-
cine when administered from day 7 after immunization. Experiments now in
progress will determine at what point after sensitization colchicine is effective in
preventing EAE.
The adoptive cell transfer experiments indicate that colchicine may act at two
different levels (Table 11). First, cultured LNG from colchicine treated animals
failed to transfer the disease. Secondly, colchicine completely prevented EAE
from developing inanimalswhen treatment was begun at thetime ofcell transfer.
Thus, it is possible that colchicine interrupts the signaling mechanism provided
by MBP-primed T cells by suppression of lymphokine secretion or by mitotic
inhibition of a critical effector population. North (6) showed that a mitosis-
inhibiting dose of vinblastin, an alkaloid similar to colchicine, could prevent the
adoptive cell transfer of immunity to listeria organisms in normal recipient mice
when immune donors were pretreated with the drug before spleen cell harvest.
Regarding the DTH experiments (Fig. 2), treatment with colchicine in the
induction phase resulted in an enhanced DTH response. Others have noted a
similar DTH enhancement after pretreatment with cytotoxic agents, notably
cyclophosphamide, and they attribute such modulation to interruption of feed-
back control of effector cells by diminished suppressor T cell activity (7) or by
suppressed specific antibody formation (8).
Additional experiments (our unpublished observations) showed that when
spleen cells from colchicine-pretreated mice were used as accessory cells in a T1808
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cell proliferation assay, a markedly enhanced proliferative response was found
compared with the response seen with splenocytes from untreated mice. Thus,
colchicine, when present during the induction phase of DTH, may stimulate
accessory cell functions resulting in enhanced T cell sensitization.
The elicitation phase of DTH is believed to involve the activation of such
sensitized T cells, leading to lymphokine secretion responsible for the activation
and focusing of effector mononuclear cells to the inflammatory site. A single
dosage of colchicine, administered at the time of antigen challenge apparently
suppressed some critical stage(s) of this effector mechanism. This result paralleled
that obtained in the adoptive cell-transfer experiment where it was shown that
colchicine, administered at the time of cell transfer, completely prevented the
development of EAE in recipients. If EAE and MS share features of a final
common efferent pathway, colchicine may prove effective in limiting lesion
development in the human disease.
Summary
Colchicine was found to inhibit the clinical and histopathological manifestations
of monophasic experimental allergic encephalomyelitis in mice. For inhibition of
actively induced disease, inoculation of colchicine at the time of encephalitogenic
challenge was found to be most effective. In adoptive transfer experiments,
lymph node cells (LNC) from colchicine treated donors failed to transfer the
disease. Additionally, colchicine treatment of recipients receiving an otherwise
disease-inducing level of sensitized LNC prevented the development of disease.
Experiments involving delayed-type hypersensitivity expression support an inhib-
itory role for the drug on event(s) of the efferent pathway of the cellular immune
response.
Receivedfor publication 11 July 1986.
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